当前位置:肿瘤瞭望>资讯>快讯>正文

ESMO ASIA 2024丨乳腺癌领域重磅研究“抢先看”

作者:肿瘤瞭望   日期:2024/10/28 16:48:19  浏览量:659

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

2024年欧洲肿瘤内科学会亚洲年会(ESMO ASIA 2024)将于当地时间12月6日~8日在新加坡召开,将展示和讨论亚洲及全球肿瘤学领域的最新科学和临床研究,这些进展将进一步推动年末的学术交流热潮!近日ESMO ASIA官网已公布相关研究题目,肿瘤瞭望特将乳腺癌领域重磅研究及中国专家投稿内容进行汇总(按出场顺序排序,如有遗漏或错误,请后台留言),以飨读者。

编者按:2024年欧洲肿瘤内科学会亚洲年会(ESMO ASIA 2024)将于当地时间12月6日~8日在新加坡召开,将展示和讨论亚洲及全球肿瘤学领域的最新科学和临床研究,这些进展将进一步推动年末的学术交流热潮!近日ESMO ASIA官网已公布相关研究题目,肿瘤瞭望特将乳腺癌领域重磅研究及中国专家投稿内容进行汇总(按出场顺序排序,如有遗漏或错误,请后台留言),以飨读者。
 
Proffered Paper session:Breast cancer
 
日期:2024年12月6日
时间:10:15-11:30
地点:Hall 404
主席:Evandro De Azambuja(Brussels,BE)Yeon Hee Park(Seoul,KR)
 
1O-A prognostic value of BCT gene score in ER+HER2-breast cancer patients with 21-gene recurrence score
BCT基因评分在经21基因复发评分评估的ER+/HER2-乳腺癌患者中的预后价值
报告时间:10:15-10:25
讲者:Sung Gwe Ahn(韩国,首尔)
 
36O-18F-fluoroestradiol(18F-FES)PET/CT guided first-line treatment for HR+/HER2-metastatic breast cancer patients:experience from real-world
18f-氟雌二醇(18F-FES)PET/CT指导HR+/HER2-转移性乳腺癌患者的一线治疗:来自真实世界的经验
报告时间:10:25-10:35
讲者:王碧芸(复旦大学附属肿瘤医院)
 
27O-Assessment of Overall Survival Benefit from Neoadjuvant Chemotherapy in Elderly HER-2 Negative Breast Cancer Patients:A Population-Based Study
评估老年HER2阴性乳腺癌患者新辅助化疗的总生存获益:一项基于人群的研究
报告时间:10:47-10:57
讲者:吕文杰(上海交通大学医学院附属新华医院)
 
2O-Analysis of Asian and non-Asian patients(pts)from the NATALEE trial of ribociclib(RIB)+a nonsteroidal aromatase inhibitor(NSAI)in pts with HR+/HER2−early breast cancer(EBC)
NATALEE研究中亚洲与非亚洲患者疗效分析:使用瑞波西利(RIB)联合非甾体芳香化酶抑制剂(NSAI)治疗HR+/HER2-早期乳腺癌(EBC)
报告时间:10:57-11:07
讲者:徐兵河(中国医学科学院肿瘤医院)
 
Mini Oral session:Breast cancer
 
日期:2024年12月7日
时间:14:30-15:40
地点:Hall 402
主席:Hiroji Iwata(Nagoya,JP)、Heekyung Ahn(Incheon,KR)、Yeon Hee Park(Seoul,KR)
 
37MO-HER2-low Heterogeneity and Its Impact on Benefit from Trastuzumab Deruxtecan in Metastatic Breast Cancer
HER2低表达的异质性及其对治疗转移性乳腺癌患者T-DXd治疗获益的影响
报告时间:14:30-14:35
讲者:邹宇田(中山大学肿瘤防治中心)
 
38MO-Datopotamab deruxtecan(Dato-DXd)vs chemotherapy(CT)in patients(pts)with pre-treated inoperable/metastatic hormone receptor-positive,HER2-negative(HR+/HER2–)breast cancer(BC):Results from TROPION-Breast01 China cohort
Datopotamab deruxtecan(Dato-DXd)vs化疗(CT)治疗既往经治的不可手术/转移性HR+/HER2-乳腺癌:TROPION-Breast01研究中国队列结果
报告时间:14:35-14:40
讲者:王树森(中山大学肿瘤防治中心)
 
3MO-Efficacy of neoadjuvant pembrolizuamb in early triple-negative breast cancer according to germline BRCA-1/2 mutation
根据胚系BRCA 1/2突变对早期三阴性乳腺癌进行帕博利珠单抗新辅助治疗的疗效
报告时间:14:55-15:00
讲者:Soong June Bae(韩国,首尔)
 
28MO-Dynamic evolution of vascular features based on magnetic resonance imaging to predict pathological response and survival outcomes in breast cancer patients undergoing neoadjuvant chemotherapy
基于磁共振成像的血管特征动态演变预测接受新辅助化疗乳腺癌患者的病理反应和生存结局
报告时间:15:00-15:05
讲者:吴琼(上海交通大学医学院附属仁济医院)
 
Poster Display session
 
日期:2024年12月7日
时间:17:50-18:45
地点:Exhibition area
 
▌Breast cancer,early stage
 
4P-Long-term outcomes of sentinel lymph node biopsy alone versus complete axillary lymph node dissection following neoadjuvant treatment in breast cancer
乳腺癌新辅助治疗后单纯进行前哨淋巴结活检与完全腋窝淋巴结清扫的长期预后比较
讲者:陈海珠(中山大学孙逸仙纪念医院)
 
10P-Predictive Value of Serum Thymidine Kinase 1 during Neoadjuvant Chemotherapy in HER2-negative Breast Cancer
血清胸腺嘧啶激酶1在HER2阴性乳腺癌新辅助化疗中的预测价值
讲者:Xintong Zhao(中国,昆明)
 
12P-A Nomogram Predicting the Long-term Survival Outcome of Neoadjuvant Therapy for Patients with Metaplastic Breast Carcinoma:A Real World Study
预测乳腺癌患者新辅助治疗长期生存结果的列线图:一项真实世界研究
讲者:Can Zhou(中国,西安)
 
20P-Exploring the impact of neoadjuvant therapy on suicide risk among breast cancer patients:A comprehensive retrospective study and mendelian randomization analysis
探索新辅助治疗对乳腺癌患者自杀风险的影响:一项全面的回顾性研究和孟德尔随机化分析
讲者:Yushuai Yu(中国,福州)
 
23P-Clinicopathological features of HR+/HER2 low breast cancer in a real-world setting in China
中国真实世界HR+/HER2低表达乳腺癌患者的临床病理特征
讲者:Zhang Min(中国,新乡)
 
26TiP-Tislelizumab combined with nab-paclitaxel,adriamycin and cyclophosphamide chemotherapy in neoadjuvant treatment in triple-negative breast cancer:A prospective,single-arm,open-label phase II study
替雷利珠单抗联合白蛋白结合型紫杉醇、阿霉素及环磷酰胺化疗用于三阴性乳腺癌新辅助治疗的疗效:一项前瞻性、单臂、开放性II期研究
讲者:Gang Zhang(中国,重庆)
 
▌Breast cancer,locally advanced
 
29P-Intratumor heterogeneity and its variation during neoadjuvant therapy is associated with treatment response and long-term prognosis in locally advanced breast cancer
局部晚期乳腺癌肿瘤内异质性及其在新辅助治疗期间的变化与治疗反应和长期预后相关
讲者:Mingxi Zhu(中国,上海)
 
39P-Estradiol suppression in premenopausal patients with hormone receptor–positive advanced breast cancer:MONALEESA-7 post hoc analysis
激素受体阳性晚期乳腺癌绝经前患者的雌二醇抑制:MONALEESA-7事后分析
讲者:Jinna Lin(中国,广州)
 
42P-Safety,tolerability,pharmacokinetics,and antitumor activity of FDA022-BB05 in patients with advanced/metastatic solid tumors:A multicenter,open-label,first-in-human,phase 1/1b study
FDA022-BB05在晚期/转移性实体瘤患者中的安全性、耐受性、药代动力学及抗肿瘤活性:一项多中心、开放性、首次人体、I/Ib期研究
讲者:Xinghe Wang(中国,北京)
 
43P-Efficacy and Safety of Paclitaxel Liposomes in Combination with Anti-HER-2 Targeted Drugs as First-Line Rescue Therapy for HER-2-Positive Locally Advanced or Metastatic Breast Cancer:A Retrospective,Real-World Study Based on the Cancer Database of China National Cancer Center(NCC)
紫杉醇脂质体联合抗HER2靶向药物作为HER2阳性局部晚期或转移性乳腺癌一线挽救治疗的疗效与安全性:基于中国国家癌症中心(NCC)癌症数据库的一项回顾性真实世界研究
讲者:Jian Yue(中国,北京)
 
49P-Ethnicity assessment of ribociclib pharmacokinetics in advanced breast cancer patients
晚期乳腺癌患者中瑞波西利药代动力学的种族差异评估
讲者:卢彦伸(中国台湾,台北)
 
50P-Establishment and validation of a predictive model for the risk and prognosis of bone metastasis in breast cancer--research based on provincial hospital data in China
乳腺癌骨转移风险及预后预测模型的建立与验证——基于中国省级医院数据的研究
讲者:Lin Miao(中国,沈阳)
 
51P-Taxane-based chemotherapy versus endocrine therapy plus CDK4/6 inhibitor as first line treatment in hormone receptor-positive HER2-negative metastatic breast cancer that progressed on adjuvant endocrine therapy
在辅助内分泌治疗后进展的激素受体阳性、HER2阴性转移性乳腺癌中,以紫杉烷类药物为基础的化疗与内分泌治疗联合CDK4/6抑制剂作为一线治疗的比较
讲者:Yang YUAN(中国,北京)
 
52P-Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer with distinct IHC statuses:Evidence from a Chinese population
T-DXd在经多重治疗且IHC状态不同的HER2低表达转移性乳腺癌中的真实世界疗效与安全性:来自中国人群的证据
讲者:Song Wu(中国,北京)
 
53P-Real-World Treatment Patterns for HER2+and HR+/HER2-Advanced Breast Cancer in County Areas of China
中国县域地区HER2+和HR+/HER2-晚期乳腺癌的真实世界治疗模式
讲者:Yinghua Ji(中国,新乡)
 
55P-A Retrospective Study to Investigate the Prevalence and Describe the Treatment Outcomes of HER2-low Unresectable and/or Metastatic Breast Cancer in Taiwan—the RetroBC-HER2L-TW Study
中国台湾地区不可切除和/或转移性HER2低表达乳腺癌的患病率调查及治疗结果描述的回顾性研究——RetroBC-HER2L-TW研究
讲者:Chih-Yi Hsu(中国台湾,台北)

 

版面编辑:张靖璇new  责任编辑:无医学编辑

本内容仅供医学专业人士参考


乳腺癌

分享到: 更多